Celltrion (068270) Investor Presentation summary

Business overview and growth

• Achieved a 30% CAGR in revenue since 2002, with significant product launches and expansion of direct sales networks in the EU and US.

• Plans to commercialize 22 biosimilar products by 2030, targeting diverse therapeutic areas and differentiated formulations.

• In-house production capacity of 250,000L in Songdo, South Korea, supporting large-scale manufacturing.

Biosimilar portfolio and market position

• Only 4 out of 65 global companies have reached annual biosimilar sales over $1 billion; Celltrion is among the leaders.

• Maintains leading market share for Remsima/Inflectra in the US and Europe, with Remsima IV + SC capturing 75% of the EU5 market.

• Yuflyma and Vegzelma sales in 1H24 exceeded their 2023 annual sales, driven by competitive advantages and bid wins in Europe.

• Direct sales network enables flexible pricing and bundling, supporting rapid sales growth in key regions.

Novel drug development

• Focused on antibody technology, aiming for clinical studies on 10+ drug candidates by 2027 across oncology, autoimmune, and metabolic diseases.

• Zymfentra, the first and only subcutaneous infliximab, achieved 75% US insurance coverage within 5 months of launch and enjoys patent protection until 2037–2040.

• Zymfentra is strongly recommended in major US treatment guidelines for IBD, with proven superior efficacy and growing market adoption.